Christopher Cannon, MD; Serge A. Jabbour, MD; Stephen Wiviott, MD
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an independent educational grant from AstraZeneca.
Thank you for joining us as we live stream the CME symposium titled, Multidimensional Outcomes in Type 2 Diabetes: Looking Beyond Hemoglobin A1c, held during the AHA Scientific Sessions 2019 in Philadelphia, Pennsylvania.
- Before we get started, please click the Pre-Questionnaire button on the right-hand side of your screen.
- Next, you will be directed to a live video feed of the program.
- Immediately following the program, please click the Posttest button on the right-hand side of your screen.
- Finally, please click the Evaluation button on the right-hand side of your screen to complete the CME evaluation and receive your certificate.
Please note: the live stream will begin at approximately 6:45pm ET (15 minutes prior to the symposium start time) and will no longer be available once the symposium ends. Live stream participants will be eligible for CME credit. There is no fee to participate in this live stream.
This program is not part of the official Scientific Sessions 2019 as planned by the AHA Committee on Scientific Sessions Program.
Christopher P. Cannon, MD
Education Director, Cardiovascular Innovation
Preventive Cardiology Section
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Serge A. Jabbour, MD, FACP, FACE
Professor of Medicine
Director, Division of Endocrinology, Diabetes and Metabolic Diseases
Sidney Kimmel Medical College
Thomas Jefferson University
Stephen D. Wiviott, MD, FACC
Executive Director, Clinical Trials Office
Thrombolysis in Myocardial Infarction (TIMI) Study Group
Cardiovascular Division, Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
The educational design of this activity addresses the needs of cardiology, endocrinology, and diabetology clinicians involved in the treatment of patients with type 2 diabetes mellitus (T2DM).
After completing this activity, the participant should be better able to:
- Describe the pathophysiologic relationships between T2DM and cardiovascular disease (CVD), heart failure (HF), and chronic kidney disease (CKD), including implications for antihyperglycemic treatment
- Compare the designs and results of large-scale cardiovascular outcomes trials with sodium-glucose cotransporter-2 (SGLT2) inhibitors for T2DM
- Discuss the mechanistic profiles, evidence for clinical benefits, and safety concerns associated with SGLT2 inhibitors as treatment options for patients with T2DM
- Collaborate with other clinicians to treat patients with T2DM based on cardiovascular and renal risks, recent guideline recommendations, and other clinical parameters
Diabetes disorders afflict more than 30 million Americans, while another 84 million adult Americans have prediabetes.1 Multisystem consequences of T2DM include CVD, HF, and CKD. The pathophysiologic mechanisms underlying T2DM, CVD, HF, and CKD share common characteristics: metabolic changes, a proinflammatory state, and oxidative stress.2 Following several cardiovascular outcomes clinical trials with SGLT2 inhibitors, the American Diabetes Association recommends incorporating these agents (and other antihyperglycemic classes, such as glucagon-like peptide-1 receptor agonists), into treatment regimens for T2DM, particularly when CVD risks are elevated.3 The established relationships among T2DM, CVD, HF, and CKD necessitate individualized treatment to avoid or mitigate hyperglycemia and these common comorbidities. Cardiologists, in particular, must be knowledgeable about how updates to guidelines outside of the cardiology space have evolved, allowing them to contribute to multidisciplinary best-practices for the treatment of patients with T2DM and common comorbidities. This live Interactive Exchange™ program will address these topics to ensure attendees understand the role of maladaptive glucose reabsorption in T2DM, the benefits SGLT2 inhibitors may have on common comorbidities associated with T2DM, and the role the cardiologist plays in diabetes management.
- Centers for Disease Control and Prevention. National diabetes statistics report. 2017; https://www.cdc.gov/diabetes/data/statistics/statistics-report.html. Accessed November 15, 2018.
- Kovacic JC, Castellano JM, Farkouh ME, Fuster V. The relationships between cardiovascular disease and diabetes: focus on pathogenesis. Endocrinol Metab Clin North Am. 2014;43(1):41-57.
- American Diabetes Association. Standard of Medical Care in Diabetes – 2019. Diabetes Care. 2019;42(suppl 1):S1-S193.
Live Program Agenda
7:00 pm Preactivity Questionnaire and Faculty Introductions
7:05 pm Mechanistic Insights Into T2DM and Common Comorbidities
7:20 pm Large-Scale Cardiovascular Outcomes Trials With SGLT2 Inhibitors
7:40 pm Tailoring Therapy For Patients With T2DM: How Can the Cardiologist Contribute?
8:00 pm Audience-Selected Case Studies
8:15 pm Postactivity Questionnaire and Q&A Session
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Physician Credit Designation
Global designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducat